Sorveglianza attiva delle patologie pneumococcicheinvasive dell'età pediatrica: l’esperienza della RegioneSicilia nel triennio 2009-2011

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

S.pneumoniae is a major cause of morbidity and mortality among children globally.Since 2007 the World Health Organization has recommended anti-pneumococcalvaccination to reduce the burden of invasive pneumococcal diseases (IPD). The aimof this study was to estimate the incidence of IPD in Sicilian children anddescribe the distribution of serotypes in subjects with IPD following the recent introduction of a universal vaccination program. Active surveillance of IPD(PneumoNet) was carried out in Sicily from 2009 to 2011 by nine referencehospitals (one per province) and one-hundred randomly sampled familypediatricians. Hospital discharge data of participating hospitals were alsoanalyzed and compared with regional surveillance data. During the three-yearsurveillance period, 136 children with a M/F ratio of 1.03 and a median age of23.5 months (range 1-57 months), were included in the study (14 in 2009, 66 in2010 and 56 in 2011). Of the 136 subjects, 43 (36.1%) were recruited from FPswhereas 93 (63.9%) from hospital personnel. Overall, 9 children (6.6%) werepositive for IPD. S. pneumoniae serotype 19A was isolated from three children,serotype 15C from three, and serotype 23F from one child. Hospital discharge datafrom 2009 to 2011 showed that a diagnosis of IPD was reported for 18 of 2,663subjects, with decreasing annual trend from 1.1% in 2009 to 0.3% in 2011(Chi-square for trend p=0.063). In conclusion, PneumoNet is shown to be aneffective tool for identifying children with IPD. The estimated incidence of IPD in Sicily is lower than that observed in other Italian and European regions,especially before vaccine introduction. These results indicate a good level ofpneumococcal disease control in the Sicilian population below 5 years of age and support the implementation of an universal vaccination program. Considering theemergence of serotypes 19A PCV13 vaccine may offer some advantages with respectto the seven-valent pneumococcal conjugate vaccine (PCV7) which does not include 19A.
Lingua originaleItalian
pagine (da-a)79-90
Numero di pagine12
RivistaIGIENE E SANITÀ PUBBLICA
Volume69
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cita questo